Research progress on the antitumor effects of astragaloside IV

Eur J Pharmacol. 2023 Jan 5:938:175449. doi: 10.1016/j.ejphar.2022.175449. Epub 2022 Dec 5.

Abstract

One of the most important and effective components of Astragalus membranaceus is astragaloside IV (AS-IV), which can exert anti-tumor effects through various pathways. For instance, AS-IV exerts an anti-tumor effect by acting at the cellular level, regulating the phenotype switch of tumor-associated macrophages, or inhibiting the development of tumor cells. Furthermore, AS-IV inhibits tumor cell progression by enhancing its sensitivity to antitumor drugs or reversing the drug resistance of tumor cells. This article reviews the different mechanisms of AS-IV inhibition of epithelial-mesenchymal transition (EMT), migration, proliferation, and invasion of tumor cells, inducing apoptosis and improving the sensitivity of anti-tumor drugs. This review summarizes recent progress in the current research into AS-IV anti-tumor effect and provides insight on the next anti-tumor research of AS-IV.

Keywords: Astragaloside IV; Drug resistance; Epithelial–mesenchymal transition; Macrophage; Sensitivity.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Astragalus propinquus
  • Epithelial-Mesenchymal Transition
  • Saponins* / pharmacology
  • Saponins* / therapeutic use
  • Triterpenes* / pharmacology
  • Triterpenes* / therapeutic use

Substances

  • astragaloside A
  • Saponins
  • Triterpenes
  • Antineoplastic Agents